Royalty Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Royalty Pharma has a total shareholder equity of $10.1B and total debt of $6.1B, which brings its debt-to-equity ratio to 60.8%. Its total assets and total liabilities are $16.4B and $6.3B respectively. Royalty Pharma's EBIT is $1.5B making its interest coverage ratio 13. It has cash and short-term investments of $495.3M.
Key information
60.8%
Debt to equity ratio
US$6.14b
Debt
Interest coverage ratio | 13x |
Cash | US$495.31m |
Equity | US$10.08b |
Total liabilities | US$6.30b |
Total assets | US$16.38b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RPRX N's short term assets ($1.3B) exceed its short term liabilities ($161.4M).
Long Term Liabilities: RPRX N's short term assets ($1.3B) do not cover its long term liabilities ($6.1B).
Debt to Equity History and Analysis
Debt Level: RPRX N's net debt to equity ratio (55.9%) is considered high.
Reducing Debt: RPRX N's debt to equity ratio has reduced from 143.2% to 60.8% over the past 5 years.
Debt Coverage: RPRX N's debt is well covered by operating cash flow (48.7%).
Interest Coverage: RPRX N's interest payments on its debt are well covered by EBIT (13x coverage).